Hitting a $100 billion valuation marks a major milestone for a drug company, but it has also been a mark that tends to be hard to grow beyond. For many drug makers, it has been sort of a hard wall, but there are reasons that may or may not be true for Moderna, according to Maxx Chatsko. In addition, Zoom spent $14.7 billion to buy Five9, an intelligent cloud contact center company. Steve Symington joins Maxx and Dan Kline to break down what the deal means. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

Most of the 7investing team joins the show to share their process for adding stocks to their personal holdings. We’ll talk about what it takes to get on our radar and when we actually make the decision to buy (as well as how we buy). We’ll also be talking investing mistakes we wish we could have back and be taking your questions live at a special 12:30 p.m. start time. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

Special purpose acquisition companies -- commonly known as "SPACs" -- are becoming increasingly popular in recent years as a way for companies to reach the public markets. While there were only 59 companies that chose to do a "SPAC IPO" in 2019, more than 360 have already taken place thus far in 2021. The total value of funds raised from those SPAC IPOs this year has exceeded $112 billion, and there are reportedly more than 300 more SPACs that have raised funds and are looking for a target. But what will the modern SPAC Race mean for investors? Is this indeed a more capital-efficient way for companies to raise money and go public? Or are investors throwing money at an unproven and potentially dangerous new trend? To answer those questions, 7investing Lead Advisors Simon Erickson and Steve Symington are digging deeper into the recent SPAC craze. In part two of their two-part podcast series, Simon and Steve dig deeper in the way that SPACs are structured and present the important factors that investors should consider. They also take a look at four SPACs that have gained a lot of attention this year -- SoFi, Ginkgo Bioworks, OpenDoor, and Rocket Lab -- and evaluate each of them as potential investment ideas. Publicly-traded companies mentioned in this podcast include Bayer, OpenDoor, SoFi, Vector Acquisition Corp, and Virgin Galactic. 7investing Lead Advisors may have positions in the companies that are mentioned. This interview was originally recorded on July 14th, 2021. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

The pandemic has led to a shortage of workers as some people have opted to not come back to the workforce for reasons ranging from childcare issues (and schools not being fully open) to others opting to keep collecting unemployment. That has forced many large companies offer wages that reach or even exceed $15 an hour. It could also make those same businesses consider they want to spend the money needed to automate their workforce. Anirban Mahanti joins Dan Kline to break down the labor market and what automation might look like.

 The restaurant industry suffered as much as any other during the pandemic. Dining rooms closed, companies had to pivot to takeout and curbside pickup. Even when dining rooms could open, they opened with limited capacities in many places. Despite that, consumers were actually fairly happy with the industry, according to results from the most recent American Customer Satisfaction Index (ACSI). David VanAmburg, Managing Director of the ACSI joined the 7investing Podcast to explain why consumers were forgiving of the restaurant industry at large despite the challenging operating environment. VanAmburg joined Dan Kline to break down why the winners in the space succeeded and why a really large brand continues to bring up the rear of the annual survey when it comes to the fast-food part of the survey. It was a very strange year, but survey scores did not move very much and very few brands saw their scores move up or down more than 1%. VanAmburg also shared his outlook for the next year and what we should be watching for.    Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year.  Start your journey toward's financial independence: https://www.7investing.com/subscribe  Stop by our website to level-up your investing education: https://www.7investing.com  Follow us on Social Media  ► https://www.facebook.com/7investing/  ► https://twitter.com/7investing  ► https://instagram.com/7investing

“Black Widow” had a great weekend at the box office, but that’s not the full story. Walt Disney also took in big bucks through people paying a premium to watch the movie through the Disney+ streaming service. Is that the new normal or an anomaly? We’ll also discuss Virgin Galactic’s successful space flight and whether the FDA will admit it made a mistake in approving a controversial Alzheimer's drug.

The facilitator of online retail has made a deal with the internet retail giant to make faster back-end services available to its customers. This is clearly an attempt by BigC to offer services that rival those offered by Shopify. The question remains -- and it’s a really big question -- is will BigCommerce’s customers want Amazon to have access to their data? The answer has been a resounding “no” in other cases where Amazon tried to offer direct merchant services, but it could be different this time. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investingofficial

Special purpose acquisition companies -- commonly known as "SPACs" -- are becoming increasingly popular in recent years as a way for companies to reach the public markets. While there were only 59 companies that chose to do a "SPAC IPO" in 2019, more than 360 have already taken place thus far in 2021. The total value of funds raised from those SPAC IPOs this year has exceeded $112 billion, and there are reportedly more than 300 more SPACs that have raised funds and are looking for a target. But what will the modern SPAC Race mean for investors? Is this indeed a more capital-efficient way for companies to raise money and go public? Or are investors throwing money at an unproven and potentially dangerous new trend? To answer those questions, 7investing Lead Advisors Simon Erickson and Steve Symington are digging deeper into the recent SPAC craze. In part one of their two-part podcast series, Simon and Steve give an overview of how SPACs are structured and why financial sponsors are incredibly important to their success. The two also discuss specific metrics that investors should be watching and specific risks they should consider. Publicly-traded companies mentioned in this podcast include Virgin Galactic and SoFi. 7investing Lead Advisors may have positions in the companies that are mentioned. This interview was originally recorded on July 8th, 2021 and was first published on the same day. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investingofficial

The Chinese government has shut down new registrations for Didi, a ride-sharing app that just had an IPO on the New York Stock Exchange. This was the biggest IPO since Alibaba in 2014 and the government’s move has investors questioning whether more regulation will be coming for other publicly-traded stocks that are based in China. Maxx Chatsko and Steve Symington join Dan Kline on the July 7 edition of “7investing Now” to figure out what this means for the long-term prospects of investing in China. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investingofficial

It's often said that biotech stocks trade on binary events, such as public disclosures of clinical trial data or regulatory approvals. That's true to some extent, but there's a bit more nuance for investors to consider. Pre-commercial drug developers don't have recurring revenue, earnings, or operating cash flow to interrogate when determining fair value, which forces Wall Street analysts and savvy investors to lean on other valuation tools. Net present value (NPV) and risk-adjusted net present value (rNPV) models can be built to account for the lack of traditional financial fundamentals and the high-risk nature of drug development. Although imperfect, these tools provide a rough, quantitative tool to properly value drug assets. For example, rNPV models can estimate the probability of success (POS) that a drug candidate in a phase 1 clinical trial will reach the market. That percentage can then be slapped onto future expected cash flows and adjusted for the time value of money to determine what the asset might be worth right now. Of course, no one knows the true POS of any single drug candidate. Wall Street analysts often plug in historical averages for specific therapeutic modalities (ex: monoclonal antibodies or kinase inhibitors) in specific therapeutic areas (ex: oncology or neurology). This modeling imperfection and crude estimation is what causes the perception of binary events. When a biotech stock craters or soars on a clinical data readout, it's often because Wall Street models are being updated all at once. Similarly, when a large drug developer pays a hefty premium to acquire a smaller peer, it's often because they're applying a much higher POS to the pipeline being acquired -- likely due to a deeper technical understanding of the science involved. In other words, there's a tremendous amount of value residing in POS differentials. If investors can build relatively accurate rNPV models that incorporate a technical understanding of the underlying drug candidates, then they should be able to stay one step ahead of Wall Street by discovering undervalued companies sooner and avoiding overvalued drug developers altogether. 7investing Lead Advisor Maxx Chatsko is learning how to build rNPV models and incorporate them into his research frameworks. In this episode of the podcast, 7investing CEO and Lead Advisor Simon Erickson chats with him about how to value biotech stocks, a high level explanation of what metrics go into these models, and how they could potentially be applied to new investing areas such as synthetic biology and industrial biotechnology. Publicly-traded companies mentioned in this podcast include Intellia Therapeutics and Johnson & Johnson. 7investing Lead Advisors may have positions in the companies that are mentioned. This interview was originally recorded on July 6th, 2021 and was first published on the same day.